AR068657A1 - Derivados de piperidina y piperazina - Google Patents
Derivados de piperidina y piperazinaInfo
- Publication number
- AR068657A1 AR068657A1 ARP080104328A ARP080104328A AR068657A1 AR 068657 A1 AR068657 A1 AR 068657A1 AR P080104328 A ARP080104328 A AR P080104328A AR P080104328 A ARP080104328 A AR P080104328A AR 068657 A1 AR068657 A1 AR 068657A1
- Authority
- AR
- Argentina
- Prior art keywords
- nnr2
- atoms
- hal
- nhet
- mono
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 abstract 2
- 101100293593 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nar-1 gene Proteins 0.000 abstract 2
- 241001103145 Pentas Species 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos de la formula (1), en donde R1 es un heterociclo insaturado o aromático bicíclico con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con A, Hal, NR2, (CR2)nCN, OR5 y/u =O (oxígeno del carbonilo); D es C o S; G es N o C, en caso de que G = N, R2 está ausente; en caso de que G = O, R2 es H o Ar1 o también junto con el átomo de C al que está unido el R2 y con E-W un radical espirocíclico seleccionado del grupo de formulas (2); Q es alquileno no ramificado o ramificado con 1, 2, 3 o 4 átomos de C, en donde 1-5 átomos de H pueden estar reemplazados por A, (CR2)n[X(CR2)n]p-Y, F y/o Cl; R3 es H, A, Ar, OR, SR, NR2, Hal, No2, CN, o (CR2)n[X(CR2)n]p-Y; X es O, NR o CR2; Y es OR o NR2; R5 es H o alquilo no ramificado o ramificado con 1, 2, 3, 4, 5 o 6 átomos de C, en donde 1-7 átomos de H pueden estar reemplazados por F y/o Cl; E es COO(CR2)n, COO(CRR4), CO(CR2)mO, CONH(CR2)n, C(=S)NH(CR2)n, S(O)qNH(CR2)n, S(O)q(CR2)n, CO(CR2)n, (CR2)n, CO(CR2)mO(CR2)n, CO(CR2)mNH(CR2)n, CO(CH2)nCO, COCHR6CHR7, C(=S)O(CR2)n, CO(CRR4)(CR2)n, COO(CRR4), (CRR4)(CR2)n, S(O)qCR=CR, COCR=CR, (CR2)mCO, CONH(CR2)mCRR4 O (CR2)mCONR; R4 es COOR5, Ar1, (CR2)nNR2, OH, NRCOOR8 o NRCOOA; R6, R7 son juntos (CH2)1-4; R8 es fenilo, naftilo o fluorenilo; R es H o alquilo no ramificado o ramificado con 1, 2, 3, 4, 5 o 6 átomos de carbono; W es Ar o Het; Ar es fenilo, indanilo, naftilo o bifenilo no sustituido o mono-, di-, tri-, tetra- o pentasustituido con Hal, A, (CR2)nOR, O(CR2)n, Ar1, (CR2)nNR2, SR, No2, CN, COOR, CONR2, NRCOA, NRSo2A, So2NR2, S(O)qA, CO-Het, (CR2)nHet, O(CR2)nNR2, O(CR2)nHet, NHCOOA, NHCONR2, NHCOO(CR2)nNR2, NHCOO(CR2)nHet, CR5=CR5Ar1, So2Het, NHCONH(CR2)nNR2, NHCONH(CR2)nHet, OCONH(CR2)nNR2, OCONH(CR2)nHet, CONR(CR2)nNR2, CONR(CR2)nHet y/o COA; Het es un heterociclo saturado, insaturado o aromático mono-, di- o tricíclico con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, (CR2)nAr1, O(CR2)nAr1, (CR2)nOR, (CR2)nNR2, SR, No2, CN, COOR, CONR2, NRCOA, NRSo2A, So2NR2, S(O)qA, CO-Het1, (CR2)nHet1, O(CR2)nNR2, O(CR2)nHet1, NHCOOA, NHCONR2, NHCOO(CR2)nNR2, NHCOO(CR2)nHet1, NHCONH(CR2)nNR2, NHCONH(CR2)nHet1, OCONH(CR2)nNR2, OCONH(CR2)nHet1, CO-Het1, CHO, COA, =S, =NH, =NA y/u =O (oxígeno del carbonilo); Het1 es un heterociclo saturado monocíclico con 1 a 2 N y/o átomos de O, que puede estar mono- o disustituido con A, OA, OH, Hal y/u =O (oxígeno del carbonilo); Ar1 es fenilo no sustituido o mono-, di-, tri-, tetra- o pentasustituido con Hal, CN, A y/o (CR2)nOR; A es alquilo no ramificado o ramificado con 1-10 átomos de C, en donde 1-7 átomos de H pueden estar reemplazados por OR, CN, NR2, F y/o Cl y/o en donde uno o dos grupos CH2 no adyacentes pueden estar reemplazados por O, NH, s, so, so2 y/o por grupos CH=CH, o alquilo cíclico con 3-7 átomos de C; m es 1, 2, 3, 4, 5 o 6; n es 0, 1, 2, 3, 4, 5, 6, 7 u 8; p es 1, 2, 3, 4, 5 o 6; q es 0, 1 o 2; Hal es F, Cl, Br o l; así como sus tautomeros, sales y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones, se pueden utilizar para el tratamiento de tumores. Medicamento en base al compuesto (y uso de este para preparar los medicamentos) y procedimiento de preparacion del compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007047737A DE102007047737A1 (de) | 2007-10-05 | 2007-10-05 | Piperidin- und Piperazinderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068657A1 true AR068657A1 (es) | 2009-11-25 |
Family
ID=40089983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104328A AR068657A1 (es) | 2007-10-05 | 2008-10-03 | Derivados de piperidina y piperazina |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8791111B2 (es) |
| EP (2) | EP2426106B1 (es) |
| JP (2) | JP5597538B2 (es) |
| KR (1) | KR20100075601A (es) |
| CN (1) | CN101808988A (es) |
| AR (1) | AR068657A1 (es) |
| AU (1) | AU2008310067B2 (es) |
| BR (1) | BRPI0817644A2 (es) |
| CA (1) | CA2701519C (es) |
| CY (2) | CY1113757T1 (es) |
| DE (1) | DE102007047737A1 (es) |
| DK (2) | DK2426106T3 (es) |
| EA (1) | EA017787B1 (es) |
| ES (2) | ES2392475T3 (es) |
| HR (2) | HRP20120802T1 (es) |
| IL (1) | IL204562A0 (es) |
| MX (1) | MX2010003366A (es) |
| PL (2) | PL2193118T3 (es) |
| PT (2) | PT2426106E (es) |
| SI (2) | SI2193118T1 (es) |
| WO (1) | WO2009046841A2 (es) |
| ZA (1) | ZA201003124B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| CA2757413C (en) * | 2009-04-02 | 2017-01-10 | Merck Patent Gmbh | Heterocyclic compounds as autotaxin inhibitors |
| DE102009049211A1 (de) * | 2009-10-13 | 2011-04-28 | Merck Patent Gmbh | Sulfoxide |
| US9353113B2 (en) | 2011-03-18 | 2016-05-31 | Ono Pharmaceutical Co., Ltd. | Tetrahydrocarboline derivative |
| US8828874B2 (en) * | 2011-03-28 | 2014-09-09 | Sinmat, Inc. | Chemical mechanical polishing of group III-nitride surfaces |
| US9273011B2 (en) * | 2011-10-28 | 2016-03-01 | Inhibitaxin Limited | Substituted pyridazines for the treatment of pain |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| BR112014025508B1 (pt) | 2012-04-13 | 2020-11-17 | Eisai R&D Management Co., Ltd. | forma de sal de um inibidor de histona metiltransferase ezh2 humana |
| MA37756B1 (fr) * | 2012-06-13 | 2018-09-28 | Hoffmann La Roche | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane |
| SI2900669T1 (sl) * | 2012-09-25 | 2019-12-31 | F. Hoffmann-La Roche Ag | Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic |
| US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
| ES2715682T3 (es) | 2012-12-19 | 2019-06-05 | Novartis Ag | Inhibidores de la autotaxina |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| WO2015042052A1 (en) | 2013-09-17 | 2015-03-26 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| JP2016530209A (ja) | 2013-09-17 | 2016-09-29 | ファーマケア，インク． | ビニルオートタキシン阻害剤化合物 |
| EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
| CN104557739B (zh) | 2013-10-25 | 2016-11-09 | 山东先达农化股份有限公司 | 三酮类化合物及其制备方法和应用 |
| HUE055213T2 (hu) | 2013-11-22 | 2021-11-29 | Sabre Therapeutics Llc | Autotaxin inhibitor vegyületek |
| JP2016537388A (ja) | 2013-11-22 | 2016-12-01 | ファーマケア，インク． | 四環系のオートタキシン阻害剤 |
| UA118201C2 (uk) | 2013-11-26 | 2018-12-10 | Ф. Хоффманн-Ля Рош Аг | НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| US20170037030A1 (en) | 2014-04-24 | 2017-02-09 | Novartis Ag | Autotaxin inhibitors |
| JPWO2015163435A1 (ja) | 2014-04-24 | 2017-04-20 | 田辺三菱製薬株式会社 | 新規２−アミノ−ピリジン及び２−アミノ−ピリミジン誘導体及びその医薬用途 |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| GB201501870D0 (en) | 2015-02-04 | 2015-03-18 | Cancer Rec Tech Ltd | Autotaxin inhibitors |
| GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| CN104758286B (zh) * | 2015-03-05 | 2016-09-14 | 南京工业大学 | 1-苄基-4-(2,4-二氯苯乙胺基)哌啶在制备抗肿瘤药物中的应用 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| CA2986759C (en) | 2015-05-27 | 2025-06-17 | Sabre Therapeutics Llc | AUTOTAXIN INHIBITORS AND THEIR USES |
| EP3302465A1 (en) | 2015-06-05 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| PE20180479A1 (es) | 2015-09-04 | 2018-03-07 | Hoffmann La Roche | Nuevos derivados de fenoximetilo |
| JP6845230B2 (ja) | 2015-09-24 | 2021-03-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物 |
| EP3353176B1 (en) | 2015-09-24 | 2022-01-19 | F. Hoffmann-La Roche AG | Bicyclic compounds as atx inhibitors |
| AU2016328535A1 (en) | 2015-09-24 | 2017-11-09 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| EP3353178B1 (en) | 2015-09-24 | 2021-07-14 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| CN110392679B (zh) | 2017-03-16 | 2023-04-07 | 豪夫迈·罗氏有限公司 | 可用作双重atx/ca抑制剂的杂环化合物 |
| US10961242B2 (en) | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
| KR101798840B1 (ko) | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
| CN107266356B (zh) * | 2017-07-25 | 2020-06-26 | 山西省生物研究院有限公司 | 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用 |
| PL3831812T3 (pl) | 2018-07-27 | 2023-09-11 | Mitsubishi Tanabe Pharma Corporation | Nowe pochodne 3,5-dipodstawionej pirydyny i 3,5-dipodstawionej pirydazyny i ich farmaceutyczne zastosowanie |
| CN112028903A (zh) * | 2020-01-17 | 2020-12-04 | 平顶山学院 | 四氢萘并呋喃酮螺吡咯烷酮化合物及其制备方法 |
| CN113461640B (zh) * | 2021-06-17 | 2023-08-11 | 中央民族大学 | Lpar1抑制剂、医药用途及其制备方法 |
| EP4405349A1 (en) * | 2021-09-21 | 2024-07-31 | Universität Münster | Autotaxin-inhibitors |
| CN114378108B (zh) * | 2022-03-24 | 2022-07-22 | 神美科技有限公司 | 一种重金属螯合剂及其在去除生活垃圾中重金属中的用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2491066A1 (fr) | 1980-09-29 | 1982-04-02 | Cerm Cent Europ Rech Mauvernay | Benzoxazolinones substituees en 6 par une chaine aminoalcool ou aminocetone, leur preparation et leur application en therapeutique |
| JPS60130573A (ja) | 1983-12-15 | 1985-07-12 | Otsuka Pharmaceut Co Ltd | ベンゾチアゾ−ル誘導体 |
| JPS6122069A (ja) * | 1984-07-06 | 1986-01-30 | Otsuka Pharmaceut Co Ltd | オキシインド−ル誘導体 |
| FR2637286A1 (fr) | 1988-10-04 | 1990-04-06 | Adir | Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2643634A1 (fr) | 1989-02-28 | 1990-08-31 | Adir | Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| US5053411A (en) | 1989-04-20 | 1991-10-01 | Anaquest, Inc. | N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| EP0567090B1 (en) * | 1992-04-24 | 2000-07-26 | Takeda Chemical Industries, Ltd. | Benzoxazepine derivatives as cholinesterase inhibitors |
| EP0709384B1 (de) * | 1994-10-31 | 1998-12-23 | MERCK PATENT GmbH | Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren |
| US6214994B1 (en) * | 1997-04-21 | 2001-04-10 | Molecular Geriatrics Corporation | Certain substituted 1-aryl-3-piperazin-1′-yl propanones |
| DE19643790A1 (de) | 1996-10-30 | 1998-05-07 | Merck Patent Gmbh | Benzoxazol-Derivat |
| US6969711B2 (en) * | 1997-05-26 | 2005-11-29 | Kowa Company, Ltd. | Cyclic diamine compounds and medicine containing the same |
| GB9725541D0 (en) | 1997-12-02 | 1998-02-04 | Pharmacia & Upjohn Spa | Amino-benzothiazole derivatives |
| PE20000728A1 (es) * | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
| EP1002535A1 (en) | 1998-10-28 | 2000-05-24 | Hrissanthi Ikonomidou | New use of glutamate antagonists for the treatment of cancer |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY |
| DE60129210T2 (de) * | 2000-02-29 | 2008-03-20 | Mitsubishi Pharma Corp. | Zyklische amid-derivate |
| DE10050236A1 (de) | 2000-10-11 | 2002-04-25 | Merck Patent Gmbh | Verwendung bestimmter Substanzen, die an den Sigma-Rezeptor binden, zur Behandlung von Sarkomen und Karzinomen |
| CA2381630A1 (en) * | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
| DE10120159A1 (de) | 2001-04-25 | 2002-10-31 | Merck Patent Gmbh | NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen |
| SK287726B6 (en) * | 2001-07-24 | 2011-07-06 | Richter Gedeon Vegyeszet | Carboxylic acid amide derivatives, their preparation, pharmaceutical compositions containing them and process for preparing pharmaceutical compositions |
| GB0320244D0 (en) * | 2003-05-06 | 2003-10-01 | Aventis Pharma Inc | Pyrazoles as inhibitors of tumour necrosis factor |
| US20070185168A1 (en) | 2004-04-07 | 2007-08-09 | Takai Haruki S | Piperidine derivatives |
| US7777037B2 (en) * | 2004-10-27 | 2010-08-17 | Dr. Reddy's Laboratories Limited | Ziprasidone process |
| TWI415845B (zh) * | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
-
2007
- 2007-10-05 DE DE102007047737A patent/DE102007047737A1/de not_active Withdrawn
-
2008
- 2008-09-19 JP JP2010527349A patent/JP5597538B2/ja not_active Expired - Fee Related
- 2008-09-19 EP EP11007349.1A patent/EP2426106B1/de not_active Not-in-force
- 2008-09-19 SI SI200830792T patent/SI2193118T1/sl unknown
- 2008-09-19 PT PT110073491T patent/PT2426106E/pt unknown
- 2008-09-19 ES ES08802402T patent/ES2392475T3/es active Active
- 2008-09-19 SI SI200831052T patent/SI2426106T1/sl unknown
- 2008-09-19 US US12/681,440 patent/US8791111B2/en not_active Expired - Fee Related
- 2008-09-19 CA CA2701519A patent/CA2701519C/en not_active Expired - Fee Related
- 2008-09-19 PT PT08802402T patent/PT2193118E/pt unknown
- 2008-09-19 HR HRP20120802AT patent/HRP20120802T1/hr unknown
- 2008-09-19 KR KR1020107009776A patent/KR20100075601A/ko not_active Ceased
- 2008-09-19 MX MX2010003366A patent/MX2010003366A/es not_active Application Discontinuation
- 2008-09-19 DK DK11007349.1T patent/DK2426106T3/da active
- 2008-09-19 PL PL08802402T patent/PL2193118T3/pl unknown
- 2008-09-19 EA EA201000549A patent/EA017787B1/ru not_active IP Right Cessation
- 2008-09-19 BR BRPI0817644 patent/BRPI0817644A2/pt not_active IP Right Cessation
- 2008-09-19 CN CN200880109583A patent/CN101808988A/zh active Pending
- 2008-09-19 EP EP08802402A patent/EP2193118B1/de not_active Not-in-force
- 2008-09-19 AU AU2008310067A patent/AU2008310067B2/en not_active Ceased
- 2008-09-19 ES ES11007349T patent/ES2429843T3/es active Active
- 2008-09-19 WO PCT/EP2008/007893 patent/WO2009046841A2/de not_active Ceased
- 2008-09-19 PL PL11007349T patent/PL2426106T3/pl unknown
- 2008-09-19 DK DK08802402.1T patent/DK2193118T3/da active
- 2008-10-03 AR ARP080104328A patent/AR068657A1/es unknown
-
2010
- 2010-03-16 IL IL204562A patent/IL204562A0/en active IP Right Grant
- 2010-05-04 ZA ZA2010/03124A patent/ZA201003124B/en unknown
-
2012
- 2012-08-22 US US13/591,765 patent/US8754097B2/en not_active Expired - Fee Related
- 2012-10-17 CY CY20121100967T patent/CY1113757T1/el unknown
-
2013
- 2013-10-03 HR HRP20130929AT patent/HRP20130929T1/hr unknown
- 2013-10-25 CY CY20131100944T patent/CY1114574T1/el unknown
-
2014
- 2014-04-09 JP JP2014079895A patent/JP5847226B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068657A1 (es) | Derivados de piperidina y piperazina | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR066543A1 (es) | Derivados de piridazinona | |
| AR066770A1 (es) | Derivados de piridazinona | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| AR068659A1 (es) | Derivados de imidazol inhibidores de autotaxina | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| AR072792A1 (es) | DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS | |
| AR067081A1 (es) | Derivados de pirrolo[2,3-b]piridin-pirimidina,proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores cancerigenos y metastasis tumorales. | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
| AR072192A1 (es) | Derivados de tiazolil-piperidina | |
| AR057214A1 (es) | Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas. | |
| AR059488A1 (es) | Hidrazidas de acido mandelico | |
| AR088919A2 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y uso | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR068748A1 (es) | Derivados de piridina activadores de glucoquinasa | |
| AR082726A1 (es) | Derivados de triazolopirazina | |
| ES2587953T3 (es) | Amidas cíclicas como inhibidores de MetAP-2 | |
| AR080326A1 (es) | Tienipirimidinas que contienen cicloalquilo para composiciones farmaceuticas | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR056519A1 (es) | 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros | |
| AR082722A1 (es) | Derivados de pirimidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |